November 16, 2012 at 14:03 PM EST
Investors Still Waiting for Decision on Amarin Fish-Oil Drug Exclusivity
MINYANVILLE ORIGINAL Since Amarin (NASDAQ:AMRN) won US approval for its fish-oil heart drug in late July there have been two topics of intense interest surrounding the company: Will it be taken over and will the new heart medicine Vascepa win a coveted protection for added market exclusivity? Investors are still waiting for answers. Amarin CEO Joseph Zakrzewski has said a takeover of the company is one of three paths for the company as it looks to launch Vascepa early next year. The drug is a pure fish-oil treatment -- more potent than over-the-counter products -- aimed at lowering triglycerides ...
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here